Mid-Atlantic BioTherapeutics

BioTech/Drugs - Doylestown, PA, US

Mid-Atlantic BioTherapeutics Employees
David Jobes

Co-Founder & President

Contact David Jobes

David Jobes

Co-Founder & President

Contact David Jobes

David Horn

Founder & CEO Mid-Atlantic BioTherapeutics, Medical Expert and Consultant

Contact David Horn

Karen Brown

Office Manager - US PPE Sales

Contact Karen Brown

Contact All Mid-Atlantic BioTherapeutics Employees
Mid-Atlantic BioTherapeutics Senior Management
David Jobes

Co-Founder & President

Contact David Jobes

David Jobes

Co-Founder & President

Contact David Jobes

David Horn

Founder & CEO Mid-Atlantic BioTherapeutics, Medical Expert and Consultant

Contact David Horn

Contact All Mid-Atlantic BioTherapeutics Employees
Mid-Atlantic BioTherapeutics Details

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body's own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called "immunotherapy". Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company's inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies for advanced Flu and Coronavirus patients.

Mid-Atlantic BioTherapeutics logo, Mid-Atlantic BioTherapeutics contact details
Website: mabt.us
Employees: 20 - 49
HQ: N/A
Location: Doylestown, PA, US
Revenue: Not Available
Immunotherapy Health Care BioTherapeutics Rabies Therapy
Mid-Atlantic BioTherapeutics Technologies
CMS

WordPress.org

Fonts

Google Font API

Hosting

GoDaddy Hosting

CSS and JavaScript Libraries

Bootstrap Framework

Online Video Platforms

YouTube

Other

Mobile Friendly

View All Technologies Used At Mid-Atlantic BioTherapeutics

Contacting Mid-Atlantic BioTherapeutics: Connect with Executives and Employees

Get in Touch with Mid-Atlantic BioTherapeutics Executives and Employees

Connecting with Mid-Atlantic BioTherapeutics's Executives and Workforce

Accessing Contact Information for Mid-Atlantic BioTherapeutics Executives

Connecting with Mid-Atlantic BioTherapeutics: Reach Out to Their Team

Discover How to Contact Mid-Atlantic BioTherapeutics Executives and Staff

Looking to connect with Mid-Atlantic BioTherapeutics executives or employees?

Seeking to Get in Touch with Mid-Atlantic BioTherapeutics Executives or Staff?

Want to Reach Out to Mid-Atlantic BioTherapeutics Executives or Team Members?

In Search of Contact Details for Mid-Atlantic BioTherapeutics Professionals?

Connecting with Mid-Atlantic BioTherapeutics: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z